Journalartikel

Jahr der Veröffentlichung: 2020

Zeitschrift: RMD Open: Rheumatic and Musculoskeletal Diseases

Bandnummer: 6

Heftnummer: 2

ISSN: 2056-5933

Open Access Status: Gold

DOI Link: https://doi.org/10.1136/rmdopen-2020-001332

Verlag: BMJ Publishing Group

Abstract: 

Objectives Patients with inflammatory rheumatic diseases (IRD) infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be at risk to develop a severe course of COVID-19. The influence of immunomodulating drugs on the course of COVID-19 is unknown. To gather knowledge about SARS-CoV-2 infections in patients with IRD, we established a registry shortly after the beginning of the pandemic in Germany.

Methods Using an online questionnaire (www.COVID19-rheuma.de.), a nationwide database was launched on 30 March 2020, with appropriate ethical and data protection approval to collect data of patients with IRD infected with SARS-CoV-2. In this registry, key clinical and epidemiological parameters-for example, diagnosis of IRD, antirheumatic therapies, comorbidities and course of the infection-are documented.

Results Until 25 April 2020, data from 104 patients with IRD infected with SARS-CoV-2 were reported (40 males; 63 females; 1 diverse). Most of them (45%) were diagnosed with rheumatoid arthritis, 59% had one or more comorbidities and 42% were treated with biological disease-modifying antirheumatic drugs. Hospitalisation was reported in 32% of the patients. Two-thirds of the patients already recovered. Unfortunately, 6 patients had a fatal course.

Conclusions In a short time, a national registry for SARS-CoV2-infected patients with IRD was established. Within 4 weeks, 104 cases were documented. The registry enables to generate data rapidly in this emerging situation and to gain a better understanding of the course of SARS-CoV2-infection in patients with IRD, with a distinct focus on their immunomodulatory therapies. This knowledge is valuable for timely information of physicians and patients with IRD, and shall also serve for the development of guidance for the management of patients with IRD during this pandemic.

Harvard-Zitierstil: Hasseli, R., Mueller-Ladner, U., Schmeiser, T., Hoyer, B., Krause, A., Lorenz, H., et al. (2020) National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD, RMD Open: Rheumatic and Musculoskeletal Diseases, 6(2), Article e001332. https://doi.org/10.1136/rmdopen-2020-001332

APA-Zitierstil: Hasseli, R., Mueller-Ladner, U., Schmeiser, T., Hoyer, B., Krause, A., Lorenz, H., Regierer, A., Richter, J., Strangfeld, A., Voll, R., Pfeil, A., Schulze-Koops, H., & Specker, C. (2020). National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD. RMD Open: Rheumatic and Musculoskeletal Diseases. 6(2), Article e001332. https://doi.org/10.1136/rmdopen-2020-001332